{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:51:36Z","timestamp":1792277496122,"version":"4.4.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R15CA290481-01A1"],"award-info":[{"award-number":["1R15CA290481-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and almost all patients relapse. Poor patient outcomes demonstrate that myeloma cells are \u201cborn to survive\u201d which means they can adapt and evolve following treatment. Thus, new therapeutic approaches to combat survival mechanisms and target treatment resistance are required. Importantly, Mcl-1, anti-apoptotic protein, is required for the development of MM and treatment resistance. This study looks at the possibility of KS18, a selective Mcl-1 inhibitor, to treat MM and overcome resistance. Our investigation demonstrates that KS18 effectively induces cell death in MM by dual regulatory mechanisms targeting the Mcl-1 protein at both transcriptional and post-translational levels. Specifically, KS18 suppresses Mcl-1 activation via STAT-3 pathway and promotes Mcl-1 phosphorylation\/ubiquitination\/proteasome-dependent protein degradation (UPS). Significantly, KS18 triggered caspase-dependent apoptosis in MM patient samples and bortezomib-resistant cells, synergizing with venetoclax to boost apoptosis. KS18 promises to overcome bortezomib and venetoclax resistance and re-sensitize myeloma cells to chemotherapy. Furthermore, the study shows the tremendous impact of KS18 in inhibiting colony formation in bortezomib-resistant cells and demonstrates significant tumor shrinkage in KS18-treated NSG mice without notable toxicity signs after 4\u00a0weeks of therapy with a single acceptable dose each week, indicating its powerful anti-neoplastic and anti-resistance characteristics. This study strongly implies that KS18 may treat MM and provide new hope to patients who are experiencing recurrence or resistance.<\/jats:p>","DOI":"10.3389\/fphar.2024.1436786","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T04:42:23Z","timestamp":1727757743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis"],"prefix":"10.3389","volume":"15","author":[{"given":"Omar S.","family":"Al-Odat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weam Othman","family":"Elbezanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishne","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantu G.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash C.","family":"Jonnalagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulin","family":"Budak-Alpdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms","volume":"4","author":"Abdi","year":"2013","journal-title":"Oncotarget"},{"key":"B2","doi-asserted-by":"publisher","first-page":"699629","DOI":"10.3389\/fphar.2021.699629","article-title":"Mcl-1 inhibition: managing malignancy in multiple myeloma","volume":"12","author":"Al-Odat","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t (14; 18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"key":"B4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1158\/0008-5472.CAN-06-3964","article-title":"Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1200\/jco.2024.42.16_suppl.6570","article-title":"A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure","volume":"42","author":"Chien","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers11050731","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"11","author":"Chong","year":"2019","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1182\/blood-2018-09-876433","article-title":"Variable BCL2\/BCL2L1 ratio in multiple myeloma with t(11;14)","volume":"132","author":"Cleynen","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ccr.2005.06.012","article-title":"Killing cancer cells by flipping the Bcl-2\/Bax switch","volume":"8","author":"Cory","year":"2005","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/cdd.2009.83","article-title":"Bax activation by Bim?","volume":"16","author":"Czabotar","year":"2009","journal-title":"Cell Death Differ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/blood.v100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1242\/jcs.038166","article-title":"Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis","volume":"122","author":"Dewson","year":"2009","journal-title":"J. cell Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4161\/15384047.2014.972799","article-title":"Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells","volume":"15","author":"Doi","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1021\/ja026939x","article-title":"HADDOCK: a protein-protein docking approach based on biochemical or biophysical information","volume":"125","author":"Dominguez","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jmb.2010.03.058","article-title":"Determinants of BH3 binding specificity for mcl-1 versus bcl-xL","volume":"398","author":"Dutta","year":"2010","journal-title":"J. Mol. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/v12020191","article-title":"Benzodiazepines drive alteration of chromatin at the integrated HIV-1 LTR","volume":"12","author":"Elbezanti","year":"2020","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"894535","DOI":"10.3389\/fphar.2022.894535","article-title":"Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells","volume":"13","author":"Elbezanti","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Garderet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/eji.200424981","article-title":"The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells","volume":"34","author":"Gomez-Bougie","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.molcel.2009.09.030","article-title":"Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis","volume":"36","author":"Kim","year":"2009","journal-title":"Mol. Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.neo.2015.07.003","article-title":"Sorafenib sensitizes glioma cells to the BH3 mimetic ABT-737 by targeting MCL1 in a STAT3-dependent manner","volume":"17","author":"Kiprianova","year":"2015","journal-title":"Neoplasia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J. Clin. investigation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas\u2014current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2002-11-3396","article-title":"Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival","volume":"102","author":"Liu","year":"2003","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/1078-0432.CCR-11-1166","article-title":"Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737","volume":"18","author":"Lucas","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"17012","DOI":"10.1038\/sigtrans.2017.12","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/cells3020418","article-title":"Mcl-1 ubiquitination: unique regulation of an essential survival protein","volume":"3","author":"Mojsa","year":"2014","journal-title":"Cells"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1\u2013expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e78570","DOI":"10.1371\/journal.pone.0078570","article-title":"Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells","volume":"8","author":"Pandey","year":"2013","journal-title":"PloS one"},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.exphem.2017.06.003","article-title":"A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis","volume":"53","author":"Pandey","year":"2017","journal-title":"Exp. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.exphem.2014.07.261","article-title":"Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways","volume":"42","author":"Pandey","year":"2014","journal-title":"Exp. Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood cancer J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"","journal-title":"Mol. cancer Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"","journal-title":"Mol. cancer Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"lancet Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","article-title":"Saga of Mcl-1: regulation from transcription to degradation","volume":"27","author":"Senichkin","year":"2020","journal-title":"Cell Death & Differ."},{"key":"B50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and regulation of pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"","journal-title":"Front. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and regulation of pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"","journal-title":"Front. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"35863","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1158\/0008-5472.CAN-11-2781","article-title":"Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome","volume":"72","author":"Tiedemann","year":"2012","journal-title":"Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuilleme-Toumi","year":"2005","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-19-1397","article-title":"AMG-176, an mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia","volume":"26","author":"Yi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.v99.6.1885","article-title":"Myeloid cell factor\u20131 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","article-title":"Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis","volume":"121","author":"Zhong","year":"2005","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2147\/DDDT.S109325","article-title":"Development of venetoclax for therapy of lymphoid malignancies","volume":"11","author":"Zhu","year":"2017","journal-title":"Drug Des. Devel Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1436786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T04:42:25Z","timestamp":1727757745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1436786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":62,"alternative-id":["10.3389\/fphar.2024.1436786"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1436786","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"article-number":"1436786"}}